BioSpace News Archive

A new approach to building AI with an automated AI App Builder for scientists to remove noise and complexity in Mass Spectrometry analysis

Phio Pharmaceuticals Corp. announced the closing of its previously announced registered direct offering of 233,646 shares of common stock, at a purchase price of $4.28 per share.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call on Monday, June 5, 2023 at 8:30 a.m. EDT.

The Board of Directors of Masimo Corporation announced its commitment to appoint Michelle Brennan as the Company’s sixth director, pending stockholder approval of the proposal to expand the Board of Directors to seven and the election of the Company’s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Ms. Brennan was nominated by Politan Capital Management.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Mersana Therapeutics, Inc. announced that on June 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 38,775 shares of its common stock and restricted stock unit awards to acquire an aggregate of 48,520 shares of its common stock, to four new employees whose employment commenced in May 2023.

Ra Medical Systems, Inc. announced financial and company highlights for the first quarter ended March 31,2023.

Jazz Pharmaceuticals plc and Zymeworks Inc. presented positive pivotal trial data, including new data on progression-free survival, from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers.

ReCode Therapeutics today announced that Angèle Maki, Ph.D., Senior Vice President, Business Development of ReCode Therapeutics, will present a company overview at 8:30 a.m. ET on Friday, June 9, 2023 at the Jefferies Healthcare Conference being held in New York, NY.

Microbot Medical Inc. (Nasdaq: MBOT) announced it has received a grant from the Israel Innovation Authority (“IIA”) in the amount of NIS 1.62 million, which based on a recent exchange rate to the U.S. dollar, would be approximately $440,000, to further support the development of the Company’s manufacturing process of its flagship robotic surgical system, the LIBERTY®.